Paul Begovatz1, Sabine Kahl1, Bettina Nowotny1, Juergen Bunke2, Michael Roden1, 3, Jong-Hee Hwang1
1Institute of Clinical Diabetology, German Diabetes Center, Duesseldorf, Germany; 2Philips Healthcare, Hamburg, Germany; 3Department of Metabolic Diseases, University Clinics, Heinrich Heine University, Duesseldorf, Germany
13C-MRS is the only method to non-invasively measure changes in net hepatic glycogen concentrations which is of interest regarding the pathophysiology of type 2 diabetes. These measurements have traditionally been conducted on MR-systems designed for spectroscopy, however expansion to FDA approved scanners would play a vital role in clinical research. Proton decoupled C1-glycogen peaks were detected with SNRs ranging from 32:1 at 514mM, to 5:1 at 106mM, with a COV=12%. Rates of net hepatic glycogen breakdown in vivo were 5.530.22 mol/kgBW/min, consistent with previous studies. This proves that the methods outlined here can be implemented for use in clinical trials.